$2.88
1.37% today
Nasdaq, Aug 12, 09:17 pm CET
ISIN
US77313F1066
Symbol
RCKT

Rocket Pharmaceuticals, Inc. Stock price

$2.92
-0.04 1.35% 1M
-6.96 70.45% 6M
-9.65 76.77% YTD
-16.03 84.59% 1Y
-13.51 82.23% 3Y
-24.26 89.26% 5Y
-48.20 94.29% 10Y
-21.08 87.83% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.06 2.10%
ISIN
US77313F1066
Symbol
RCKT
Industry

Key metrics

Basic
Market capitalization
$315.1m
Enterprise Value
$18.2m
Net debt
positive
Cash
$318.2m
Shares outstanding
106.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 28.4
EV/Sales
- | 1.6
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
87.8%
Return on Equity
-55.9%
ROCE
-62.0%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $11.1m
EBITDA
$-260.1m | $-240.7m
EBIT
$-270.2m | $-247.8m
Net Income
$-258.0m | $-241.6m
Free Cash Flow
$-212.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-1.1% | 8.8%
EBIT
-2.0% | 9.3%
Net Income
-3.5% | 6.6%
Free Cash Flow
-1.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -2,172.1%
EBIT
-
Net
- | -2,180.0%
Free Cash Flow
-
More
EPS
$-2.3
FCF per Share
$-2.0
Short interest
23.3%
Employees
299
Rev per Employee
$0.0
Show more

Is Rocket Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Rocket Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

14x Buy
58%
9x Hold
38%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:

Buy
58%
Hold
38%
Sell
4%

Financial data from Rocket Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 108 108
39% 39%
-
- Research and Development Expense 162 162
13% 13%
-
-260 -260
1% 1%
-
- Depreciation and Amortization 10 10
32% 32%
-
EBIT (Operating Income) EBIT -270 -270
2% 2%
-
Net Profit -258 -258
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Rocket Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rocket Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
one day ago
NEW YORK--(BUSINESS WIRE)---- $RCKT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Neutral
PRNewsWire
2 days ago
NEW YORK , Aug. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the "Class Period"), of the important August 11, 2025 lead plaintiff deadline. So what: If you purchased Rocket Pharmaceuticals securities during the Cla...
Neutral
PRNewsWire
4 days ago
PHILADELPHIA , Aug. 8, 2025 /PRNewswire/ --  Berger Montague PC , a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") on behalf of investors who suffered losses due to alleged material misstatements and omissions. If you purcha...
More Rocket Pharmaceuticals, Inc. News

Company Profile

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Head office United States
CEO Gaurav Shah
Employees 299
Founded 1999
Website www.rocketpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today